Simponi (golimumab) / Merck (MSD), Tanabe Pharma, J&J - LARVOL DELTA

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "Ixekizumab, tofacitinib, and golimumab are all cost-effective options for PsA. These findings support phenotype-guided therapeutic decisions and highlight the influence of drug pricing."

HEOR • Journal • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review. (PubMed, Mediterr J Rheumatol) - "Uveitis exposure-adjusted incidence rates per 100 patient years (EAIR/100PY) ranged between 0-4.5 for tumour necrosis factor inhibitors (TNFi), 0.5-3.9 for interleukin-17 inhibitors (IL-17i) and 0.8-3.3 for upadacitinib (UPA), as derived from available RCTs. Evidence from non-RCTs, reporting uveitis incidence rates per 100PY, ranged between 3.46-55.2 for etanercept, 1.38-15.7 for adalimumab, 1.82-25.9 for infliximab, 1.39-6.8 for golimumab, 0-9.4 for secukinumab and 0 for ixekizumab...IL-17i are identified as second line treatment option especially in uveitis refractory to TNFi. Finally, JAKi remain a promising alternative, with more evidence needed to further establish their so far proven efficacy."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Ocular Inflammation • Oncology • Ophthalmology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL17A

Clinical Features and Outcome of Patients With Juvenile Spondyloarthropathy in a Tertiary Hospital in the Philippines. (PubMed, Clin Pediatr (Phila)) - "The JSpA in this cohort demonstrated substantial disease burden, with frequent axial and peripheral involvement. Although 43.2% of patients achieved clinical remission, sustained remission off medication was observed in only 10.2%, reflecting the chronic disease course. Early diagnosis and optimized treatment strategies remain essential to improve outcomes."

Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Oncology • Pediatrics • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • TNFA

Cardiovascular Adverse Events of JAK vs. TNF Inhibitors using the Korean Pharmacovigilance Database. (PubMed, Cardiology) - "Methods Adverse event (AE) reports between January 1, 2015 and December 31, 2020 of JAK-Is (tofacitinib or baricitinib) or TNF-Is (adalimumab, etanercept, or golimumab) were included. These trends were particularly notable in women (CVEs: ROR: 7.52, 95% CI: 3.06-18.47) and in patients over 50 years old (CVEs: ROR: 5.01, 95% CI: 2.02-12.43). Conclusion This disproportionality analysis using a national pharmacovigilance database identified reporting signals for total CVEs with JAK-Is compared to TNF-Is; in particular, a significant signal for thrombosis was observed."

Adverse events • Journal • Cardiovascular • Hematological Disorders • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Thrombosis

Stand UP to Rheumatoid Arthritis (SUPRA) (clinicaltrials.gov) - P=N/A | N=75 | Recruiting | Sponsor: Marie Hudson, MD | Trial completion date: Dec 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2028

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Hepatobiliary disorders associated with TNF-α inhibitors: a pharmacovigilance analysis of FAERS and JADER. (PubMed, Front Immunol) - "We analyzed the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) data and Japanese Adverse Drug Event Report Database (JADER) data for five TNF-a inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) listed as primary suspects. Male sex and skin and subcutaneous tissue disorders were regarded as consistent independent risk factors. The factors of drug dose, body weight, and additional comorbidity clusters could also require attention in clinics because these factors were obviously observed in certain single databases."

Adverse events • Journal • Hepatology • Oncology • Rheumatology

Sequencing Patterns and Efficacy of Biological Therapies and Small Molecules in Patients with Ulcerative Colitis: A Single-Center Retrospective Study (ECCO-IBD 2026) - "Patients underwent 78 courses of advanced therapy (Infliximab 30, Adalimumab 11, Golimumab 8, Vedolizumab 22, Ustekinumab 1, Tofacitinib 2, Filgotinib 2, Ozanimod 2). Conclusion Advanced biologic and small-molecule therapies were effective and generally well-tolerated in patients with refractory UC. Infliximab showed the most durable first-line treatment response, whereas Adalimumab was associated with a shorter treatment duration."

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic Disease. (PubMed, Am J Gastroenterol) - "Among biologic-naïve UC patients with severe endoscopic disease, infliximab and upadacitinib had the highest rates of week 2 and post-induction PRO-2 response. Baseline disease activity may help to better inform treatment choices."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis. (PubMed, Mod Rheumatol Case Rep) - "Re-induction with methylprednisolone pulse and methotrexate (MTX) led to slight improvement. Subsequent therapy with tocilizumab (TCZ), followed by golimumab (GLM), resulted in significant and sustained improvement in the stenosis...Comprehensive disease assessment using imaging modalities, alongside serum biomarkers, is essential to guide therapeutic decisions and monitor vascular changes. These findings highlight the importance of imaging-based disease monitoring and raise the potential for targeted treatment strategies aimed at both inflammation control and vascular lesion modification."

Journal • Cardiovascular • Immunology • Inflammation • Vasculitis

Effectiveness of First- and Second-Line Advanced Therapy in Microscopic Colitis: A Real-World Cohort Study (ECCO-IBD 2026) - "First-line therapies encompassed vedolizumab (VDZ, n=8), infliximab (IFX, n=11), and adalimumab (ADA, n=3)...Second-line therapy was initiated in 9 patients (VDZ n=5, IFX n=2, ustekinumab [UST] n=2)...Third-line therapy was applied in 5 patients (VDZ n=2, UST n=1, risankizumab n=1, and upadacitinib [UPA] n=1)...Two patients received fourth-line therapy with golimumab and failed to achieve clinical remission...Advanced therapies represent a promising treatment option in refractory MC. However, prospective controlled studies are urgently needed to confirm these findings and to define optimal treatment strategies for MC."

Clinical • Metastases • Real-world • Real-world evidence • Immunology • Inflammatory Bowel Disease

Identification of a Molecular Signature of Disease Severity in Ulcerative Colitis Using a Systems Biology Approach and Clinical Impact Using VARSITY Trial Data (ECCO-IBD 2026) - "Signature module involvement was assessed using disease model data from 1985 mucosal biopsies from 18 UC clinical studies, including pts treated with golimumab, infliximab or vedolizumab. Validation across multiple real-world registries and clinical trials highlights its potential as a biomarker for clinical evaluation and the gene panel size relative to prior work offers enhanced feasibility for use to define residual disease burden in pts with endoscopic and histologic improvements in disease activity. This is an important step towards precision medicine in IBD using a molecular endotype-based classification of UC."

Clinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Patient profile at baseline in the Kazakhstan IBD registry: a cross-sectional analysis of the initial visit (ECCO-IBD 2026) - "Ustekinumab was used significantly more often in Crohn’s disease (13.9% vs. 2.3%, p < 0.001), whereas golimumab was administered exclusively to patients with ulcerative colitis (5.8%, p < 0.001). The registry also revealed gaps in clinical practice requiring improved management. Overall, these findings outline the initial clinical profile and treatment patterns of IBD patients in Kazakhstan."

Clinical • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis

Safety and effectiveness of advanced therapies in patients with Inflammatory Bowel Disease and compensated cirrhosis. Preliminary data from the HEP-IBD study. A study from the young group of GETECCU (ECCO-IBD 2026) - "Consecutive IBD patients with an established diagnosis cirrhosis (Child A or Child B≤8) who received at least induction with infliximab, adalimumab, golimumab, ustekinumab, vedolizumab, tofacitinib, upadacitinib, risankizumab, mirikizumab or filgotinib between January 2000 and September 2024, were eligible. Conclusion This preliminary data indicates that the use of advanced therapies is viable in compensated cirrhosis, with acceptable treatment persistence rates alongside a low risk of hepatic decompensation, particularly for non-anti-TNF therapies. Nonetheless, caution is warranted given the potential risk of adverse events."

Clinical • Metastases • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Utilising Advanced Therapies in Inflammatory Bowel Disease: Real-World Experience from a UK Centre (ECCO-IBD 2026) - "Biologics and small-molecule medications included anti-TNFα (Adalimumab, Infliximab IV/SC, Golimumab), anti-integrin (Vedolizumab IV/SC), anti-IL12/23 (Ustekinumab), anti-IL23 (Risankizumab), JAK inhibitors (Tofacitinib, Upadacitinib, Filgotinib), and anti-IL23p19 (Mirikizumab)...The observed shift toward subcutaneous Infliximab and Vedolizumab is consistent with global trends that support self-administration and service efficiency...Conclusion Although there is a substantial variability between consultants, the adoption of biologics within this large NHS Trust is consistent with national and international prescribing trends. The results corroborate the need for multidisciplinary assessment and standardization of biologic initiation pathways in order to optimize equality and consistency in advanced IBD treatment."

Clinical • Metastases • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL12A • IL23A

Impact of concomitant mesalazine administration on the efficacy and safety of advanced therapies in ulcerative colitis: a meta-analysis over the induction and maintenance phases (ECCO-IBD 2026) - "Methods A meta-analysis of RCTs including approved biological agents (Adalimumab,Infliximab,Golimumab,Mirikizumab,Guselkumab,Ozanimod,Etrasimod,Ustekinumab) and small molecules (Tofacitinib,Upadacitinib) in UC patients reporting concomitant msz use was conducted through a search of four databases. Conclusion The concomitant use of msz and advanced therapies is associated with improved mucosal healing during maintenance therapy for UC, suggesting a potential synergistic effect in the long term. Future prospective studies incorporating histologic outcomes are warranted to elucidate the mechanistic contribution of msz in combination regimens."

Metastases • Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Monitoring serum αvβ6 antibodies during induction vedolizumab therapy is a strong and drug-selective predictor of sustained clinical remission in UC at one year (ECCO-IBD 2026) - "Methods Real-world data were collected from two multicentric, prospective, observational studies, one including patients with IBD treated with VDZ the (VEDOPREDIRESP) and the second one including UC patients treated with intensified golimumab (GOLILOR) . Conclusion Serum αvβ6 antibodies are novel accurate markers to discriminate UC from CD. In UC patients, monitoring serum αvβ6 antibodies titers during induction with VDZ is a strong and drug specific predictor associated with sustained clinical remission at one year and might be of paramount interest to guide clinician’s decision."

Clinical • Inflammatory Bowel Disease • Ulcerative Colitis

Differences in the prescription of advanced therapies for patients with Crohn's disease and ulcerative colitis in the Brazilian public health system (SUS) versus the Private Health system (PS) in a Brazilian state. "Portrait of a Country with Two Realities" (ECCO-IBD 2026) - "Ustekinumab predominated in the PS N=45 (39.5%) while infliximab predominated in the SUS N=44 (37.9%). In ulcerative colitis (UC), vedolizumab prescription predominated in the SUS N=49 (53.8%) and PS N=20 (43.4%) (p>0.05)...Ustekinumab N=9 (19.5%) (p<0.05) and Golimumab N=8 (17.3%) (p<0.05) were only prescribed in the PS. Tofacitinib predominated in the SUS n=17 (18.6%) vs PS n=2 (4%) (p<0.05). Conclusion We observed a significant difference in education and income between IBD patients assisted in the public system versus the private system. The difference in prescriptions between the SUS (Brazilian Public Health System) and the PS (Private Health System) occurred mainly with molecules not included in the Ministry's protocol or the ANS (National Supplementary Health Agency) list, suggesting that "access" can directly impact prescriptions for IBD patients."

Clinical • Metastases • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Impact of Corticosteroid Therapy on Long-term Treatment Outcomes in Ulcerative Colitis: A Retrospective Cohort Study (ECCO-IBD 2026) - "Recent availability of carotegrast methyl and oral budesonide has expanded treatment options before AT initiation, necessitating re-evaluation of CS use strategies...AT breakdown: infliximab/adalimumab/golimumab/vedolizumab/ustekinumab/upadacitinib/tofacitinib/filgotinib = 37/20/15/15/7/2/1/1...Cumulative CS dose ≥3,000 mg increases the risk of refractory disease 4.35-fold. These findings suggest that early transition to AT should be considered in elderly-onset patients, and cumulative CS dose of 3,000 mg may serve as a useful threshold for treatment strategy modification, potentially contributing to individualised UC management."

Retrospective data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Safety of dual-targeted therapy in Inflammatory Bowel Disease: a systematic review (ECCO-IBD 2026) - "In total, 230 dual-therapy combinations were reported: tofacitinib/tumor necrosis factor-alpha inhibitor (anti-TNFα), n = 1; tofacitinib/vedolizumab, n = 13, golimumab/guselkumab, n = 71; adalimumab/vedolizumab, n = 55; anti-TNFα/vedolizumab, n = 41; anti-TNFα/anti-interleukin (anti-IL) agent, n = 11; anti-IL/vedolizumab, n = 21; anti-IL/anti-IL, n = 1; other combinations, n = 16. Anti-TNFα combinations demonstrated significantly higher SAEs rates, whereas vedolizumab-based regimens showed fewer infections. Evidence for small-molecule combinations remains limited, highlighting the need for larger prospective research."

Clinical • Review • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Fighting on all fronts: golimumab to the rescue for steroid-refractory CNS TB–IRIS in an HIV-positive patient facing extreme psychosocial vulnerability (ESCMID Global 2026) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

Response to Advanced Therapies in Chronic Pouchitis Is Independent of Exposure to Similar Advanced Therapy in Ulcerative Colitis before Colectomy (ECCO-IBD 2026) - "The biologic and small-molecule agents used for chronic pouchitis treatment included vedolizumab, infliximab, ustekinumab, adalimumab, mirikizumab, golimumab, upadacitinib, and risankizumab. Conclusion Prior exposure to advance therapy before colectomy did not significantly affect response to subsequent advanced therapy initiation in chronic pouchitis. Patients previously exposed to infliximab showed increased rates of adverse events related to immunogenicity upon reintroduction."

Metastases • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report. (PubMed, Cureus) - "We report the case of a 63-year-old male patient with rheumatoid arthritis (RA) who experienced Epstein-Barr virus (EBV) reactivation during treatment with methotrexate (MTX) and anti-tumor necrosis factor-alpha (TNF-α) antibody, golimumab (GLM)...Two months later, RA relapsed and was managed with prednisolone, bucillamine, and salazosulfapyridine, but disease activity persisted. GLM was reintroduced one year after EBV reactivation, resulting in sustained remission without EBV-related complications, despite continued positivity for viral markers. This case highlights the potential feasibility of resuming anti-TNF-α antibody therapy in patients with RA exhibiting prolonged EBV reactivation and sustained IgM seropositivity under close monitoring."

Journal • Epstein-Barr Virus Infections • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Infliximab infusion reactions in Immune Checkpoint Inhibitor Colitis: a comparative study with Inflammatory Bowel Disease (ECCO-IBD 2026) - "Three patients were subsequently treated with golimumab (n = 2 attained remission), and one went successfully into remission with vedolizumab. Conclusion Despite substantial risk factors comprising episodic therapy and highly activated state of immune response, the risk of acute severe infusion reactions to IFX does not appear to be increased in patients with ICI-C compared to IBD. Switching to another TNF-inhibitor can be successful following a reaction."

Checkpoint inhibition • Immunology • Inflammation • Inflammatory Bowel Disease

Progressive interstitial lung disease associated with rheumatoid arthritis and abatacept: data from a multicenter cohort of 526 patients. (PubMed, Rheumatology (Oxford)) - "Despite ABA therapy, progressive ILD occurred in nearly one-quarter of RA patients.ABA showed good tolerability and maintained pulmonary and rheumatologic stability in most cases. However, prior treatments and joint disease activity may help to predict the risk of ILD progression."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology